Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis

Archive ouverte

Carvelli, Julien | Demaria, Olivier | Vély, Frédéric | Batista, Luciana | Chouaki Benmansour, Nassima | Fares, Joanna | Carpentier, Sabrina | Thibult, Marie-Laure | Morel, Ariane | Remark, Romain | André, Pascale | Represa, Agnès | Piperoglou, Christelle | Cordier, Pierre Yves | Le Dault, Erwan | Guervilly, Christophe | Simeone, Pierre | Gainnier, Marc | Morel, Yannis | Ebbo, Mikael | Schleinitz, Nicolas | Vivier, Eric | Assante Miranda, Laura | Baron, William | Belaid, Nourhène | Caillet, Clarisse | Caraguel, Flavien | Carrette, Barbara | Carrette, Florent | Chanuc, Fabien | Courtois, Rachel | Fenis, Aurore | Giordano, Marilyn | Girard-Madoux, Mathilde | Giraudon-Paoli, Marc | Gourdin, Nicolas | Grondin, Gwendoline | Guillot, Franceline | Habif, Guillaume | Jaubert, Solène | Lopez, Julie | Le Van, Mélanie | Lovera, Naouel | Mansuy, Marine | Bonnet, Elodie | Sansaloni, Audrey | Reboul, Annick | Mitry, Emmanuel | Nekkar-Constant, Camille | Péri, Valentine | Ricaut, Paul | Simon, Léa | Vallier, Jean-Baptiste | Vétizou, Marie | Zerbib, Robert | Ugolini, Sophie | Etiennot, Marion | Galluso, Justine | Lyonnet, Luc | Forel, Jean-Marie | Papazian, Laurent | Velly, Lionel | André, Baptiste | Briantais, Antoine | Faucher, Benoit | Jean, Estelle | Seguier, Julie | Veit, Veronique | Harlé, Jean-Robert | Pastorino, Boris | Delteil, Clémence | Daniel, Laurent | Boudsocq, Jean-Paul | Clerc, Axelle | Delmond, Emmanuel | Vidal, Pierre-Olivier | Savini, Hélène | Coutard, Bruno

Edité par CCSD -

International audience. Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic1. The C5a complement factor and its receptor C5aR1 (also known as CD88) have a key role in the initiation and maintenance of several inflammatory responses by recruiting and activating neutrophils and monocytes1. Here we provide a longitudinal analysis of immune responses, including phenotypic analyses of immune cells and assessments of the soluble factors that are present in the blood and bronchoalveolar lavage fluid of patients at various stages of COVID-19 severity, including those who were paucisymptomatic or had pneumonia or acute respiratory distress syndrome. The levels of soluble C5a were increased in proportion to the severity of COVID-19 and high expression levels of C5aR1 receptors were found in blood and pulmonary myeloid cells, which supports a role for the C5a-C5aR1 axis in the pathophysiology of acute respiratory distress syndrome. Anti-C5aR1 therapeutic monoclonal antibodies prevented the C5a-mediated recruitment and activation of human myeloid cells, and inhibited acute lung injury in human C5aR1 knock-in mice. These results suggest that blockade of the C5a-C5aR1 axis could be used to limit the infiltration of myeloid cells in damaged organs and prevent the excessive lung inflammation and endothelialitis that are associated with acute respiratory distress syndrome in patients with COVID-19.

Suggestions

Du même auteur

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant

Archive ouverte | Demaria, Olivier | CCSD

International audience. Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating recepto...

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Archive ouverte | Carvelli, Julien | CCSD

International audience. OBJECTIVES: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. DESIGN: FOR COVID ...

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Archive ouverte | Andre, Pascale | CCSD

International audience. Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor ...

Chargement des enrichissements...